High cholesterol rarely shows up alone. It often occurs alongside obesity, hypertension, and diabetes—quietly stacking cardiovascular risk over years. By adding Omada for Cholesterol to our integrated platform, we’re addressing high cholesterol as part of the same cardiometabolic system as weight, blood pressure, and diabetes. Members get between‑visit support that helps implement daily lifestyle changes to actively manage high cholesterol alongside other risks. Learn more: https://lnkd.in/dxV4X4M3
😵💫 The GLP-1 market is getting more complex for employers and members alike with multiple injectables, multiple orals, fragmented access, and rapidly shifting benefit designs. Employers don’t need another point solution; they need help navigating. Omada meets that need with a spectrum of GLP‑1 services—companion lifestyle care, prescribing, and flexible benefit pathways, so organizations can provide support and meet their members where they’re at, without rebuilding their strategy every quarter. Learn more: https://lnkd.in/dk8DSZR5
In trial data, nearly 40% of weight loss from GLP-1 patients came from lean mass. That’s almost half! Why should individuals and organizations care? Our latest whitepaper breaks down how loss of lean mass can undermine long-term GLP-1 weight loss outcomes. Read it now. https://lnkd.in/g7huaUes
In this member + coach spotlight, see how Omada’s health coaches help people take real‑life obstacles and turn them into small, confident steps—checking blood pressure, taking a short walk, choosing a nutritious meal—that add up over time for better health. We call this compassionate intelligence: human care teams supported by AI, working together to help deliver tangible outcomes across key metrics. Learn more: https://lnkd.in/d6qDdGwb
Our nutrition experience, powered by OmadaSpark built on Amazon SageMaker AI, is trained on clinical protocols, peer‑reviewed literature, and specialty guidelines so members get safe, context-aware education informed by their conditions and goals in real time with meaningful interactions.So when members need help at the moment - standing in their kitchen or looking at a menu, they’re not alone: OmadaSpark can help them navigate emotional eating and make choices that align with the care plan built with their care team. Learn more about how we built the experience with AWS AI and AI at Meta: https://lnkd.in/di4uSZr6
GLP‑1 Flex Care gives employers a way to offer their workforce access to anti‑obesity medications—even when traditional coverage isn’t financially feasible. Through established cash‑pay channels, members who independently obtain their prescriptions can access Omada’s wraparound care: from prescription to lifestyle counseling to ongoing clinical oversight, all the way through safe discontinuation. GLP-1 Flex Care will be available to employers later in 2026. Want to learn more about our new offering? https://lnkd.in/eDx3Wj6R
We're proud to share $OMDA's Q1 2026 results as proof that growth and durability can compound together, even in our most cost-intensive quarter: 📈 Revenue up 42% YoY to $78M 👥 Total Members surpassed 1M for the first time, up 51% YoY 📉 GAAP net loss narrowed to $3M (vs. $9M in Q1 2025) 💫 Positive adjusted EBITDA, even in our historically highest-cost quarter Click in to see how we’re delivering on our four growth levers - these proof points reinforce that Omada is becoming part of the connective tissue between how employers buy, how members engage, and how outcomes are delivered across the digital cardiometabolic landscape. Full Q1 2026 release with GAAP to non-GAAP reconciliation: https://lnkd.in/dF7wPJJB
Last week, we hosted an esteemed group of consultants in Nashville for our roundtable, GLP‑1s + AI: Powering the Next Era of Cardiometabolic Care. Over two days, thought leaders explored the rapidly evolving AI policy landscape with Ben Moscovitch and examined how AI is transforming cardiometabolic care with insights from Dr. Faraz Ahmad. We also shared Omada’s latest AI-powered innovations, along with real-world GLP‑1 outcomes—including muscle mass preservation and sustained weight management. Thank you to the consultants who joined us, our expert speakers and partners, and the Omada team who brought this program to life. We look forward to continuing the conversation and collaborating to shape the next era of cardiometabolic care.
Join Horizon Day 2026 for a LinkedIn Live reveal of how Omada is redefining cardiometabolic care as GLP-1s reshape the obesity treatment landscape. Don't miss Omada's Sean Duffy and Wei-Li Shao as they showcase Omada’s integrated approach, including a walk-through of GLP-1 prescribing and the guided medication care experience. They'll also reveal the strategy and vision shaping the future of Omada's care model. We’ll be taking audience Q&A in real time during the event, so join us—and join the conversation.
For employers, the real GLP‑1 budget question isn’t just “What do they cost?”—it’s “What do we get for our spend?” Omada acts as a GLP‑1 value maximizer. Our GLP‑1 Care Track includes nutrition guidance, human coaching, and behavior‑change support around medication to improve persistence, manage side effects, and support healthy discontinuation so results last. Our research has shown that members in Omada’s GLP‑1 program achieved greater weight loss and better weight maintenance on average than real world evidence. Not all access is created equal - learn more about how to maximize value from the investment in this piece by Wei-Li Shao: https://lnkd.in/dcsC6h7k
